Tuilleadh fiosrachaidh ― Scots gaelic

Is e suidheachadh tearc a th’ ann an Urticarial vasculitis a tha air a chomharrachadh le tachartasan maireannach no ath‑chuairteachadh de shnàthadan. Ged a dh’fhaodadh na comharran craicinn a bhith coltach ri corragan leantainneach, tha iad gun samhail le bhith a’ cumail na sràcan timcheall airson co-dhiù 24 uair, agus faodaidh iad spotan dorcha adhbhrachadh às deidh crìonadh. Ged a tha e tric gun adhbhar aithnichte, uaireannan faodaidh e a bhith air a phiobrachadh le cungaidhean sònraichte, galairean, galairean fèin‑dìon, eas‑òrdughan fala no cansearan. Tha cuid de sgrùdaidhean eadhon a’ ceangal ri cnatan mòr COVID‑19 agus H1N1. Faodaidh e cuideachd buaidh a thoirt air pàirtean eile den bhodhaig leithid fèithean, dubhagan, sgamhanan, stamag, agus sùilean. Ged a dh'fhaodas seòrsa sònraichte de sgrùdadh clò a dhearbhadh air a 'bhreithneachadh, chan eil e an‑còmhnaidh riatanach. Mar as trice, bidh làimhseachadh a’ tòiseachadh le antibiotics, dapsone, colchicine no hydroxychloroquine airson cùisean nas ciùine. Airson cùisean nas cruaidhe, dh’fhaodadh gum feum drogaichean a chuireas stad air an t‑siostam dìon, leithid methotrexate no corticosteroids. O chionn ghoirid, tha leigheasan bith‑eòlais (rituximab, omalizumab, interleukin‑1 inhibitors) air gealltanas a nochdadh airson cùisean duilich.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.

Thàinig fireannach 35 bliadhna a dh'aois le eachdraidh de 15 latha de bhroth dearg, goirt air gach sliasaid agus casan, agus pian co‑phàirteach. Bha galar slighe urain air feadh seachdain mus do nochd am broth. Sheall a chraiceann grunn chlàran dearga, tairgse, cumadh fàinne, gu ìre so‑ruigsinneach air gach taobh a shliasaid agus a chasan. Chaidh prednisolone beòil (40 mg/ latha) a thoirt dha airson seachdain, còmhla ri antihistamine neo‑truagh (fexofenadine). Aig deireadh na seachdain, chaidh na brògan gu lèir à sealladh. Cha robh brot eile ann am na 6 mìosan a tha romhainn, a rèir sgrùdaidhean cunbhalach.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.